The US Food and Drug Administration has issued an official complete response letter to Eli Lilly and Company for the immuno-oncology agent, Tvvyt (sintilimab), developed by its partner Innovent Biologics, Inc.
The CRL follows an expert committee vote in February that recommended rejecting the approval of the first anti-PD-1 antibody from...